Table 3.
Characteristics of clients and services provided by the integrated care van in 6 neighborhoods in Baltimore, Maryland from September 2018 to March 2020.
| Characteristics and services | Overall | N1 | N31 | N6 | N7 | N10 | N12 |
|---|---|---|---|---|---|---|---|
| ICV factors | |||||||
| Date services started | SEP 20182 | SEP 2018 | SEP 2018 | NOV 2018 | FEB 2019 | JUL 2019 | NOV 2019 |
| Date services ended | MAR 20202 | MAR 2020 | APR 2019 | MAR 2020 | MAR 2020 | MAR 2020 | MAR 2020 |
| Months of service, n | 18.32 | 18.2 | 6.9 | 15.4 | 12.4 | 8.3 | 3.9 |
| Total client visits, n | 4,0782 | 1,535 | 68 | 1,139 | 683 | 450 | 203 |
| Unique clients, n | 7342 | 248 | 33 | 184 | 126 | 94 | 49 |
| Client characteristics | |||||||
| Age (years), median (P25, P75) |
48.4 (34.9, 55.5) |
45.0 (33.6, 54.9) |
40.8 (31.8, 55.0) |
48.4 (36.4, 55.0) |
50.4 (40.0, 56.8) |
51.0 (36.8, 56.4) |
50.9 (34.7, 56.4) |
| Female, n (%) | 242 (33.0) | 82 (33.1) | 19 (57.6) | 65 (35.3) | 34 (27.0) | 27 (28.7) | 15 (30.6) |
| Race, n (%) | |||||||
| Black | 573 (78.1) | 151 (60.9) | 18 (54.6) | 171 (92.9) | 103 (81.7) | 89 (94.7) | 41 (83.7) |
| White | 145 (19.7) | 89 (35.9) | 14 (42.4) | 9 (4.9) | 20 (15.9) | 5 (5.3) | 8 (16.3) |
| Other | 16 (2.2) | 8 (3.2) | 1 (3.0) | 4 (2.2) | 3 (2.4) | 0 (0.0) | 0 (0.0) |
| Hispanic, n (%) | 6 (0.8) | 4 (1.6) | 0 (0.0) | 0 (0.0) | 2 (1.6) | 0 (0.0) | 0 (0.0) |
| Visits attended, n (%) | |||||||
| 1–2 | 333 (45.4) | 102 (41.1) | 29 (87.8) | 73 (39.7) | 65 (51.6) | 39 (41.5) | 25 (51.0) |
| 3–8 | 256 (34.9) | 90 (36.3) | 2 (6.1) | 70 (38.0) | 34 (27.0) | 43 (45.7) | 17 (34.7) |
| >8 | 145 (19.7) | 56 (22.6) | 2 (6.1) | 41 (22.3) | 27 (21.4) | 12 (12.8) | 7 (14.3) |
| Active injection drug use3 | 126 (17.2) | 80 (32.3) | 7 (21.2) | 12 (6.5) | 7 (5.6) | 18 (19.2) | 2 (4.1) |
| Unique clients receiving services | |||||||
| POC HIV test, n (%) | 577 (78.6) | 177 (71.4) | 22 (66.7) | 146 (79.4) | 110 (87.3) | 79 (84.0) | 43 (87.8) |
| HIV positive test, n (%) | 19 (2.6) | 3 (1.2) | 1 (3.0) | 2 (1.1) | 4 (3.2) | 3 (3.2) | 6 (12.2) |
| New HIV diagnosis, n (%) | 3 (0.4) | 0 (0.0) | 1 (3.0) | 1 (0.5) | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Treated for HIV on ICV, n (%) | 4 (0.5) | 4 (1.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| HCV antibody test, n (%) | 525 (71.5) | 153 (61.7) | 18 (54.6) | 145 (78.8) | 102 (81.0) | 73 (77.7) | 34 (69.4) |
| Positive HCV antibody, n (%) | 119 (16.2) | 50 (20.2) | 2 (6.1) | 18 (9.8) | 28 (22.2) | 13 (13.8) | 8 (16.3) |
| HCV RNA measured, n (%) | 109 (14.9) | 43 (17.3) | 3 (9.1) | 14 (7.6) | 27 (21.4) | 10 (10.6) | 12 (24.5) |
| HCV RNA detectable, n (%) | 70 (9.5) | 25 (10.1) | 2 (6.1) | 8 4.4) | 19 (15.1) | 8 (8.5) | 8 (16.3) |
| Treated for HCV on ICV, n (%) | 21 (2.9) | 11 (4.4) | 1 (3.0) | 1 (0.5) | 5 (4.0) | 1 (1.1) | 2 (4.1) |
| Screened for STI4, n (%) | 602 (82.0) | 190 (76.6) | 20 (60.6) | 162 (88.0) | 108 (85.7) | 80 (85.1) | 42 (85.7) |
| Tested positive for STI, n (%) | 60 (8.2) | 20 (8.1) | 3 (9.1) | 18 (9.8) | 9 (7.1) | 7 (7.5) | 3 (6.1) |
| Treated for STI, n (%) | 42 (5.7) | 15 (6.1) | 1 (3.0) | 12 (6.5) | 7 (5.6) | 5 (5.3) | 2 (4.1) |
| Wound care provided, n (%) | 35 (4.8) | 19 (7.7) | 1 (3.0) | 8 (4.4) | 4 (3.2) | 1 (1.1) | 2 (4.1) |
| PrEP prescribed, n (%) | 18 (2.5) | 6 (2.4) | 0 (0.0) | 5 (2.7) | 6 (4.8) | 1 (1.1) | 0 (0.0) |
| Naloxone overdose kit distributed, n (%) | 342 (46.6) | 73 (29.4) | 10 (30.3) | 94 (51.1) | 70 (55.6) | 58 (61.7) | 37 (75.5) |
| Initiated BUP/NX, n (%) | 540 (73.6) | 177 (71.4) | 16 (48.5) | 152 (82.6) | 92 (73.0) | 70 (74.5) | 33 (67.4) |
N1, N3, N6, N7, N10, N12: neighborhood sites assigned to integrated care van; ICV, integrated care van; P25 and P75, 25th percentile and 75th percentile, respectively; POC, point-of-care; HCV, hepatitis C virus; STI, sexually transmitted infection; PrEP, pre-exposure prophylaxis; BUP/NX, buprenorphine/naloxone
Site N3 was slow to accrue clients and service to this site was discontinued approximately 6 months after initiating.
Median across sites
Active injection drug use defined as notation of recent injection drug use in the baseline ICV clinical assessment or a visit to the health department’s syringe services program within 3 months before or after an ICV visit.
Screening for sexually transmitted infection included serologic syphilis testing and urine nucleic acid amplification for N. gonorrhea and C. trachomatis